source
- FDA grants accelerated approval for Etcamah combo therapy for advanced HR-positive, HER2-negative breast cancerThe U.S. Food and Drug Administration announced accelerated approval of Etcamah (camizestrant) in combination with a CDK4/6 inhibitor for adult patients with hormone-receptor-positive, HER2-negativ…
- Funding shortfall threatens progress of new Ebola vaccine candidatesA rapidly expanding Ebola outbreak in Africa has spurred multiple groups to accelerate vaccine development. The effort is being coordinated by a key global health organization, but the group is fa…